Page last updated: 2024-09-05

cilengitide and Blood Diseases

cilengitide has been researched along with Blood Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Böttcher, S; Brindley, C; Drevs, J; Dumez, H; Eskens, FA; Hoekstra, R; Perschl, A; van Oosterom, AT; Verweij, J; Wynendaele, W	1

Trials

1 trial(s) available for cilengitide and Blood Diseases

Article	Year
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:7 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Integrin alphaVbeta3; Integrins; Male; Middle Aged; Neoplasms; Receptors, Vitronectin; Snake Venoms	2003

Article

Year

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.

European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:7

Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Integrin alphaVbeta3; Integrins; Male; Middle Aged; Neoplasms; Receptors, Vitronectin; Snake Venoms

2003